FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Philippe Soubrié

Research Profile

Living Beings

Chemicals & Drugs

Concepts & Ideas

Drug Dose Response Relationship

Anatomy

Activities & Behaviors

Co-author Network

Publications

TOP 3
Magali Gary-Bobo; Ghizlane Elachouri; Jean François Gallas; Philip Janiak; Pietro Marini; Christine Ravinet Trillou; Michèle Chabbert; Noël Cruccioli; Christian Pfersdorff; Claude Roque; Michèle Arnone; Tiziano Croci; Philippe Soubrié; Florence Oury-Donat; Jean-Pierre Maffrand; Bernard Scatton; Frederic Lacheretz; Gérard Le-Fur; Jean-Marc Herbert; Mohammed Bensaid
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.
Ronan Depoortère; Gihad Dargazanli; Genevieve Estenne-Bouhtou; Annick Coste; Christophe Lanneau; Christophe Desvignes; Martine Poncelet; Michel Heaulme; Vincent Santucci; Michel Decobert; Annie Cudennec; Carolle Voltz; Denis Boulay; Jean-Paul Terranova; Jeanne Stemmelin; Pierre Roger; Benoit Marabout; Mireille Sevrin; Xavier Vigé; Bruno Biton; Régis Steinberg; Dominique Françon; Richard Alonso; Patrick Avenet; Florence Oury-Donat; Ghislaine Perrault; Guy Griebel; Pascal Guy GEORGE; Philippe Soubrié; Bernard Scatton
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Omar Jbilo; Christine Ravinet Trillou; Michèle Arnone; Isabelle Buisson; Estelle Bribes; Annick Péleraux; Géraldine Pénarier; Philippe Soubrié; Gérard Le-Fur; Sylvaine Galiègue; Pierre Casellas
The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Philippe Soubrié (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Magali Gary-Bobo; Ghizlane Elachouri; Jean François Gallas; Philip Janiak; Pietro Marini; Christine Ravinet Trillou; Michèle Chabbert; Noël Cruccioli; Christian Pfersdorff; Claude Roque; Michèle Arnone; Tiziano Croci; Philippe Soubrié; Florence Oury-Donat; Jean-Pierre Maffrand; Bernard Scatton; Frederic Lacheretz; Gérard Le-Fur; Jean-Marc Herbert; Mohammed Bensaid
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.
Hepatology (Baltimore, Md.) 2007;46(1):122-9.
2005: Ronan Depoortère; Gihad Dargazanli; Genevieve Estenne-Bouhtou; Annick Coste; Christophe Lanneau; Christophe Desvignes; Martine Poncelet; Michel Heaulme; Vincent Santucci; Michel Decobert; Annie Cudennec; Carolle Voltz; Denis Boulay; Jean-Paul Terranova; Jeanne Stemmelin; Pierre Roger; Benoit Marabout; Mireille Sevrin; Xavier Vigé; Bruno Biton; Régis Steinberg; Dominique Françon; Richard Alonso; Patrick Avenet; Florence Oury-Donat; Ghislaine Perrault; Guy Griebel; Pascal Guy GEORGE; Philippe Soubrié; Bernard Scatton
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(11):1963-85.
2005: Omar Jbilo; Christine Ravinet Trillou; Michèle Arnone; Isabelle Buisson; Estelle Bribes; Annick Péleraux; Géraldine Pénarier; Philippe Soubrié; Gérard Le-Fur; Sylvaine Galiègue; Pierre Casellas
The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(11):1567-9.
2005: Guy Griebel; Jeanne Stemmelin; Claudine Serradeil-Le Gal; Philippe Soubrié
Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.
Current pharmaceutical design 2005;11(12):1549-59.
2005: Caroline Cohen; Ghislaine Perrault; Guy Griebel; Philippe Soubrié
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(1):145-55.
2004: Frédéric Lallemand; Philippe Soubrié; Philippe De Witte
Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic alcohol administration combined with repeated re-exposures and withdrawals.
Alcohol and alcoholism (Oxford, Oxfordshire) 2004;39(6):486-92.
2004: Murielle Rinaldi-Carmona; Francis Barth; Christian Congy; Serge Martinez; Didier Oustric; Alain Pério; Martine Poncelet; Jeanne Maruani; Michèle Arnone; Olivier Finance; Philippe Soubrié; Gérard Le-Fur
SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.
The Journal of pharmacology and experimental therapeutics 2004;310(3):905-14.
2004: Denis Boulay; Ronan Depoortère; C Louis; Ghislaine Perrault; Guy Griebel; Philippe Soubrié
SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats.
Neuropharmacology 2004;46(8):1121-9.
2004: Jean Gougat; Bernard Ferrari; Lionel Sarran; Claudine Planchenault; Martine Poncelet; Jeanne Maruani; Richard Alonso; Annie Cudennec; Tiziano Croci; Fabio Guagnini; Katalin Urban-Szabo; Jean-Pierre Martinolle; Philippe Soubrié; Olivier Finance; Gérard Le-Fur
SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization.
The Journal of pharmacology and experimental therapeutics 2004;309(2):661-9.
2004: Christine Duarte; Richard Alonso; Nicole Bichet; Caroline Cohen; Philippe Soubrié; Marie-Hélène Thiébot
Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004;29(5):911-20.
2004: Maud Leonetti; Philippe Brun; Magali Clerget; Régis Steinberg; Philippe Soubrié; Bernard Renaud; Marie-Françoise Suaud-Chagny
Specific involvement of neurotensin type 1 receptor in the neurotensin-mediated in vivo dopamine efflux using knock-out mice.
Journal of neurochemistry 2004;89(1):1-6.
2004: Christine Ravinet Trillou; C Delgorge; C Menet; Michèle Arnone; Philippe Soubrié
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 2004;28(4):640-8.
2004: Richard Alonso; Guy Griebel; G Pavone; Jeanne Stemmelin; G Le Fur; Philippe Soubrié
Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
Molecular psychiatry 2004;9(3):278-86, 224.
2004: Christine Roubert; C Spielewoy; Philippe Soubrié; M Hamon; Bruno GIROS; Catalina Betancur
Altered neurotensin mrna expression in mice lacking the dopamine transporter.
Neuroscience 2004;123(2):537-46.
2003: Yves Claustre; Danielle De Peretti; Philippe Brun; Christiane Gueudet; Nathalie Allouard; Richard Alonso; Joëlle Lourdelet; André Oblin; Gabrielle Damoiseau; Dominique Françon; Marie-Françoise Suaud-Chagny; Régis Steinberg; Mireille Sevrin; Hans Schoemaker; Pascal Guy GEORGE; Philippe Soubrié; Bernard Scatton
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(12):2064-76.
2003: Ronan Depoortere; Denis Boulay; Ghislaine Perrault; Olivier E Bergis; Michel Decobert; Dominique Françon; Mireille Jung; Jacques Simiand; Philippe Soubrié; Bernard Scatton
SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(11):1889-902.
2003: Marie-Louise Kemel; Sylvie Pérez; Jean-Claude Beaujouan; Maritza Jabourian; Philippe Soubrié; Jacques Glowinski
The new neurokinin 1-sensitive receptor mediates the facilitation by endogenous tachykinins of the NMDA-evoked release of acetylcholine after suppression of dopaminergic transmission in the matrix of the rat striatum.
Journal of neurochemistry 2003;87(2):487-96.
2003: Martine Poncelet; Jeanne Maruani; Roselyne Calassi; Philippe Soubrié
Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice.
Neuroscience letters 2003;343(3):216-8.
2003: Christophe Desvignes; Liliane Rouquier; J Souilhac; G Mons; Daniel Rodier; Philippe Soubrié; Régis Steinberg
Control by tachykinin NK(2) receptors of CRF(1) receptor-mediated activation of hippocampal acetylcholine release in the rat and guinea-pig.
Neuropeptides 2003;37(2):89-97.
2003: Mohammed Bensaid; Magali Gary-Bobo; A Esclangon; Jean-Pierre Maffrand; Gérard Le-Fur; Florence Oury-Donat; Philippe Soubrié
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
Molecular pharmacology 2003;63(4):908-14.
2002: Régis Steinberg; Richard Alonso; Liliane Rouquier; Christophe Desvignes; Jean-Claude Michaud; Annie Cudennec; Mireille Jung; Jacques Simiand; Guy Griebel; Xavier Emonds-Alt; Gérard Le-Fur; Philippe Soubrié
SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization.
The Journal of pharmacology and experimental therapeutics 2002;303(3):1180-8.
2002: Xavier Emonds-Alt; Vincenzo Proietto; Régis Steinberg; Florence Oury-Donat; Xavier Vigé; Pol Vilain; Emmanuel Naline; Samira Daoui; Charles Advenier; Gérard Le-Fur; Jean-Pierre Maffrand; Philippe Soubrié; Marc Pascal
SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
The Journal of pharmacology and experimental therapeutics 2002;303(3):1171-9.
2002: Pascale Chardenot; Christine Roubert; Sylvaine Galiègue; Pierre Casellas; Gérard Le-Fur; Philippe Soubrié; Florence Oury-Donat
Expression profile and up-regulation of PRAX-1 mRNA by antidepressant treatment in the rat brain.
Molecular pharmacology 2002;62(6):1314-20.
2002: Anne Remaury; Natalio VITA; Sylvain Gendreau; Mireille Jung; Michèle Arnone; Martine Poncelet; Jean-Michel Culouscou; Gérard Le-Fur; Philippe Soubrié; Daniel Caput; David Shire; Manfred Kopf; Pascual Ferrara
Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia.
Brain research 2002;953(1-2):63-72.
2002: C Cohen; Ghislaine Perrault; Carolle Voltz; Régis Steinberg; Philippe Soubrié
SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.
Behavioural pharmacology 2002;13(5-6):451-63.
2002: Paul C Moser; Olivier E Bergis; Samir Jegham; Alistair Lochead; Elee Duconseille; Jean-Paul Terranova; Dominique Caille; Isabelle Berque-Bestel; Frank Lezoualc'h; Rodolphe Fischmeister; Aline Dumuis; Joël Bockaert; Pascal Guy GEORGE; Philippe Soubrié; Bernard Scatton
SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
The Journal of pharmacology and experimental therapeutics 2002;302(2):731-41.
2002: Maud Leonetti; Philippe Brun; Florence Sotty; Régis Steinberg; Philippe Soubrié; Lionel Bert; Bernard Renaud; Marie-Françoise Suaud-Chagny
The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area.
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(6):427-33.
2002: Xavier Emonds-Alt; Vincenzo Proietto; Régis Steinberg; Charles Advenier; Samira Daoui; Emmanuel Naline; Christiane Gueudet; Jean-Claude Michaud; Florence Oury-Donat; Martine Poncelet; Pol Vilain; Gérard Le-Fur; Jean-Pierre Maffrand; Philippe Soubrié; Marc Pascal
Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist.
Canadian journal of physiology and pharmacology 2002;80(5):482-8.
2002: Guy Griebel; Jacques Simiand; Régis Steinberg; Mireille Jung; Danielle Gully; Pierre Roger; Michel Geslin; Bernard Scatton; Jean-Pierre Maffrand; Philippe Soubrié
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders.
The Journal of pharmacology and experimental therapeutics 2002;301(1):333-45.
2002: Marie-Louise Kemel; Sylvie Pérez; Gérard Godeheu; Philippe Soubrié; Jacques Glowinski
Facilitation by endogenous tachykinins of the NMDA-evoked release of acetylcholine after acute and chronic suppression of dopaminergic transmission in the matrix of the rat striatum.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(5):1929-36.
2002: Claudine Serradeil-Le Gal; Jean Wagnon; Jacques Simiand; Guy Griebel; Colette Lacour; Gilles Guillon; Claude Barberis; Gabrielle Brossard; Philippe Soubrié; Dino Nisato; Marc Pascal; Rebecca PRUSS; Bernard Scatton; Jean-Pierre Maffrand; Gérard Le-Fur
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
The Journal of pharmacology and experimental therapeutics 2002;300(3):1122-30.
2002: Lionel Bert; Daniel Rodier; Isabelle Bougault; Nathalie Allouard; Gérard Le-Fur; Philippe Soubrié; Régis Steinberg
Permissive role of neurokinin NK(3) receptors in NK(1) receptor-mediated activation of the locus coeruleus revealed by SR 142801.
Synapse (New York, N.Y.) 2002;43(1):62-9.
2001: A Pério; M C Barnouin; Martine Poncelet; Philippe Soubrié
Activity of SR141716 on post-reinforcement pauses in operant responding for sucrose reward in rats.
Behavioural pharmacology 2001;12(8):641-5.
2001: Guy Griebel; N Moindrot; C Aliaga; Jacques Simiand; Philippe Soubrié
Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery.
Neuroscience and biobehavioral reviews 2001;25(7-8):619-26.
2001: Régis Steinberg; Richard Alonso; Guy Griebel; Lionel Bert; Mireille Jung; Florence Oury-Donat; Martine Poncelet; Christiane Gueudet; Christophe Desvignes; Gérard Le-Fur; Philippe Soubrié
Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function.
The Journal of pharmacology and experimental therapeutics 2001;299(2):449-58.
2001: Philippe Brun; Maud Leonetti; Florence Sotty; Régis Steinberg; Philippe Soubrié; Bernard Renaud; Marie-Françoise Suaud-Chagny
Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist.
Journal of neurochemistry 2001;77(6):1542-52.
2001: Mohammed Bensaid; B A Faucheux; Etienne C Hirsch; Yves Agid; Philippe Soubrié; Florence Oury-Donat
Expression of tachykinin NK2 receptor mRNA in human brain.
Neuroscience letters 2001;303(1):25-8.
2000: Jean-Claude Michaud; Christiane Gueudet; Philippe Soubrié
Effects of neurotensin receptor antagonists on the firing rate of rat ventral pallidum neurons.
Neuroreport 2000;11(7):1437-41.
2000: F Blanchet; Christian Gauchy; Sylvie Pérez; Philippe Soubrié; Jacques Glowinski; Marie-Louise Kemel
Control by GABA and tachykinins of the evoked release of acetylcholine in striatal compartments under different modalities of NMDA receptor stimulation.
Brain research 2000;853(1):142-50.
2000: Florence Sotty; Philippe Brun; Maud Leonetti; Régis Steinberg; Philippe Soubrié; Bernard Renaud; Marie-Françoise Suaud-Chagny
Comparative effects of neurotensin, neurotensin(8-13) and [D-Tyr(11)]neurotensin applied into the ventral tegmental area on extracellular dopamine in the rat prefrontal cortex and nucleus accumbens.
Neuroscience 2000;98(3):485-92.
1999: Christiane Gueudet; Vincent Santucci; Philippe Soubrié; Gérard Le-Fur
Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs.
Synapse (New York, N.Y.) 1999;33(1):71-9.
1999: Martine Poncelet; M C Barnouin; JC Brelière; Gérard Le-Fur; Philippe Soubrié
Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils.
Psychopharmacology 1999;144(2):144-50.
1999: C Labie; C Lafon; C Marmouget; P Saubusse; J Fournier; Peter Keane; Gérard Le-Fur; Philippe Soubrié
Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex.
British journal of pharmacology 1999;127(1):139-44.
1999: E Bignon; Richard Alonso; Michèle Arnone; R Boigegrain; R Brodin; Christiane Gueudet; M Héaulme; Peter Keane; Marco Landi; J C Molimard; D Olliero; Martine Poncelet; E Seban; Jacques Simiand; Philippe Soubrié; Marc Pascal; Jean-Pierre Maffrand; Gérard Le-Fur
SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.
The Journal of pharmacology and experimental therapeutics 1999;289(2):752-61.
1999: E Bignon; A Bachy; R Boigegrain; R Brodin; M Cottineau; Danielle Gully; Jean-Marc Herbert; Peter Keane; C Labie; J C Molimard; D Olliero; Florence Oury-Donat; C Petereau; V Prabonnaud; M P Rockstroh; Paul Schaeffer; O Servant; O Thurneyssen; Philippe Soubrié; Marc Pascal; Jean-Pierre Maffrand; Gérard Le-Fur
SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
The Journal of pharmacology and experimental therapeutics 1999;289(2):742-51.
1999: Richard Alonso; H Gnanadicom; N Fréchin; M Fournier; Gérard Le-Fur; Philippe Soubrié
Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain.
The European journal of neuroscience 1999;11(3):967-74.
1999: Richard Alonso; B Voutsinos; M Fournier; C Labie; Régis Steinberg; J Souilhac; Gérard Le-Fur; Philippe Soubrié
Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function.
Neuroscience 1999;91(2):607-20.
1998: N Marco; A Thirion; G Mons; Isabelle Bougault; Gérard Le-Fur; Philippe Soubrié; Régis Steinberg
Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig.
Neuropeptides 1998;32(5):481-8.
1998: M Héaulme; R Leyris; Philippe Soubrié; Gérard Le-Fur
Stimulation by neurotensin of (3H)5-hydroxytryptamine (5HT) release from rat frontal cortex slices.
Neuropeptides 1998;32(5):465-71.
1998: E Nalivaiko; Jean-Claude Michaud; Philippe Soubrié; Gérard Le-Fur
Electrophysiological evidence for putative subtypes of neurotensin receptors in guinea-pig mesencephalic dopaminergic neurons.
Neuroscience 1998;86(3):799-811.
1998: Florence Sotty; Fabienne Soulière; Philippe Brun; Guy Chouvet; Régis Steinberg; Philippe Soubrié; Bernard Renaud; Marie-Françoise Suaud-Chagny
Differential effects of neurotensin on dopamine release in the caudal and rostral nucleus accumbens: a combined in vivo electrochemical and electrophysiological study.
Neuroscience 1998;85(4):1173-82.
1998: F Blanchet; Christian Gauchy; S Perez; Philippe Soubrié; Jacques Glowinski; Marie-Louise Kemel
Distinct modifications by neurokinin1 (SR140333) and neurokinin2 (SR48968) tachykinin receptor antagonists of the N-methyl-D-aspartate-evoked release of acetylcholine in striosomes and matrix of the rat striatum.
Neuroscience 1998;85(4):1025-36.
1998: F H T Duong; J Fournier; Peter Keane; J L Guénet; Philippe Soubrié; Jean-Marie Warter; J Borg; Philippe Poindron
The effect of the nonpeptide neurotrophic compound SR 57746A on the progression of the disease state of the pmn mouse.
British journal of pharmacology 1998;124(4):811-7.
1998: Régis Steinberg; J Souilhac; Daniel Rodier; Richard Alonso; Xavier Emonds-Alt; Gérard Le-Fur; Philippe Soubrié
Facilitation of striatal acetylcholine release by dopamine D1 receptor stimulation: involvement of enhanced nitric oxide production via neurokinin-2 receptor activation.
Neuroscience 1998;84(2):511-8.
1998: Jacques Simiand; M Keane; Peter Keane; Philippe Soubrié
SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.
Behavioural pharmacology 1998;9(2):179-81.
1998: J Fournier; G Boutot; Peter Keane; Jean-Pierre Maffrand; Gérard Le-Fur; Philippe Soubrié
The non-peptide neuroprotective agents SR 57746A interacts with neurotrophin 3 to induce differentiation in the PC12 cell-line.
The Journal of pharmacy and pharmacology 1998;50(3):323-7.
1998: Frederique CHAPERON; Philippe Soubrié; A J Puech; Marie-Hélène Thiébot
Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats.
Psychopharmacology 1998;135(4):324-32.
1998: Jean-Claude Michaud; Richard Alonso; Christiane Gueudet; M Fournier; Roselyne Calassi; JC Brelière; Gérard Le-Fur; Philippe Soubrié
Effects of SR140333, a selective non-peptide NK1 receptor antagonist, on trigemino-thalamic nociceptive pathways in the rat.
Fundamental & clinical pharmacology 1998;12(1):88-94.
1997: Xavier Emonds-Alt; Charles Advenier; C Cognon; Tiziano Croci; Samira Daoui; J P Ducoux; Marco Landi; Emmanuel Naline; G Neliat; Martine Poncelet; Vincenzo Proietto; D Van Broeck; Pol Vilain; Philippe Soubrié; Gérard Le-Fur; Jean-Pierre Maffrand; JC Brelière
Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonist.
Neuropeptides 1997;31(5):449-58.
1997: Vincent Santucci; Christiane Gueudet; Régis Steinberg; Gérard Le-Fur; Philippe Soubrié
Involvement of cortical neurotensin in the regulation of rat meso-cortico-limbic dopamine neurons: evidence from changes in the number of spontaneously active A10 cells after neurotensin receptor blockade.
Synapse (New York, N.Y.) 1997;26(4):370-80.
1997: Michèle Arnone; Jeanne Maruani; Frederique CHAPERON; Marie-Hélène Thiébot; Martine Poncelet; Philippe Soubrié; Gérard Le-Fur
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.
Psychopharmacology 1997;132(1):104-6.
1997: E Nalivaiko; Jean-Claude Michaud; Philippe Soubrié; Gérard Le-Fur; P Feltz
Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study.
Neuroscience 1997;78(3):745-57.
1997: Danielle Gully; B Labeeuw; R Boigegrain; Florence Oury-Donat; A Bachy; Martine Poncelet; Régis Steinberg; Marie-Françoise Suaud-Chagny; Vincent Santucci; Natalio VITA; F Pecceu; CATHERINE LABBE-JULLIE; Patrick Kitabgi; Philippe Soubrié; Gérard Le-Fur; Jean-Pierre Maffrand
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.
The Journal of pharmacology and experimental therapeutics 1997;280(2):802-12.
1997: M Jung; Roselyne Calassi; Murielle Rinaldi-Carmona; P Chardenot; Gérard Le-Fur; Philippe Soubrié; Florence Oury-Donat
Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A.
Journal of neurochemistry 1997;68(1):402-9.
1996: M Jung; Jean-Claude Michaud; Régis Steinberg; M C Barnouin; A Hayar; G Mons; J Souilhac; Xavier Emonds-Alt; Philippe Soubrié; Gérard Le-Fur
Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation.
Neuroscience 1996;74(2):403-14.
1996: J P Terranova; J P Kan; J J Storme; P Perreaut; Gérard Le-Fur; Philippe Soubrié
Administration of amyloid beta-peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non-peptide neurotrophic compound.
Neuroscience letters 1996;213(2):79-82.
1996: J P Terranova; J J Storme; N Lafon; A Péŕio; Murielle Rinaldi-Carmona; Gérard Le-Fur; Philippe Soubrié
Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716.
Psychopharmacology 1996;126(2):165-72.
1996: Richard Alonso; M Fournier; P Carayon; G Petitpretre; Gérard Le-Fur; Philippe Soubrié
Evidence for modulation of dopamine-neuronal function by tachykinin NK3 receptor stimulation in gerbil mesencephalic cell cultures.
The European journal of neuroscience 1996;8(4):801-8.
1996: Murielle Rinaldi-Carmona; F Pialot; C Congy; E Redon; Francis Barth; A Bachy; JC Brelière; Philippe Soubrié; Gérard Le-Fur
Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
Life sciences 1996;58(15):1239-47.
1996: Vincent Santucci; J J Storme; Philippe Soubrié; Gérard Le-Fur
Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis.
Life sciences 1996;58(6):PL103-10.
1995: Régis Steinberg; Daniel Rodier; J Souiclhac; I Bougault; Xavier Emonds-Alt; Philippe Soubrié; Gérard Le-Fur
Pharmacological characterization of tachykinin receptors controlling acetylcholine release from rat striatum: an in vivo microdialysis study.
Journal of neurochemistry 1995;65(6):2543-8.
1995: J P Terranova; Jean-Claude Michaud; Gérard Le-Fur; Philippe Soubrié
Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Naunyn-Schmiedeberg's archives of pharmacology 1995;352(5):576-9.
1995: Christiane Gueudet; Vincent Santucci; Murielle Rinaldi-Carmona; Philippe Soubrié; Gérard Le-Fur
The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat.
Neuroreport 1995;6(10):1421-5.
1995: Florence Oury-Donat; P Carayon; O Thurneyssen; V Pailhon; Xavier Emonds-Alt; Philippe Soubrié; Gérard Le-Fur
Functional characterization of the nonpeptide neurokinin3 (NK3) receptor antagonist, SR142801 on the human NK3 receptor expressed in Chinese hamster ovary cells.
The Journal of pharmacology and experimental therapeutics 1995;274(1):148-54.
1995: Régis Steinberg; Daniel Rodier; G Mons; D Gully; Gérard Le-Fur; Philippe Soubrié
SR 48692-sensitive neurotensin receptors modulate acetylcholine release in the rat striatum.
Neuropeptides 1995;29(1):27-31.
1995: J Souilhac; Martine Poncelet; M Rinaldi-Carmona; Gérard Le-Fur; Philippe Soubrié
Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice.
Pharmacology, biochemistry, and behavior 1995;51(1):3-7.
1995: C Labie; P Saubusse; Peter Keane; Gérard Le-Fur; Philippe Soubrié
Effects of the sigma receptor ligand SR 31742A on neurotensin biosynthesis in rat basal ganglia.
Synapse (New York, N.Y.) 1995;19(4):241-6.
1995: D Gully; F Jeanjean; Martine Poncelet; Régis Steinberg; Philippe Soubrié; Gérard Le-Fur; Jean-Pierre Maffrand
Neuropharmacological profile of non-peptide neurotensin antagonists.
Fundamental & clinical pharmacology 1995;9(6):513-21.
1995: Murielle Rinaldi-Carmona; Francis Barth; M Héaulme; R Alonso; David Shire; C Congy; Philippe Soubrié; JC Brelière; Gérard Le-Fur
Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.
Life sciences 1995;56(23-24):1941-7.
1995: D Gully; Jean-Pierre Maffrand; Philippe Soubrié; William Rostène; Patrick Kitabgi; Gérard Le-Fur
[Neurotensin receptor antagonists and therapeutical perspectives].
Thérapie 1995;50(1):5-7.
1995: Régis Steinberg; P Brun; J Souilhac; I Bougault; R Leyris; Gérard Le-Fur; Philippe Soubrié
Neurochemical and behavioural effects of neurotensin vs [D-Tyr11]neurotensin on mesolimbic dopaminergic function.
Neuropeptides 1995;28(1):43-50.
1994: Martine Poncelet; J Souilhac; Christiane Gueudet; J P Terranova; D Gully; Gérard Le-Fur; Philippe Soubrié
Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats.
Psychopharmacology 1994;116(2):237-41.
1994: M Didier; J M Mienville; Philippe Soubrié; J Bockaert; Stephen Alan Berman; Sherry Bursztajn; J P Pin
Plasticity of NMDA receptor expression during mouse cerebellar granule cell development.
The European journal of neuroscience 1994;6(10):1536-43.
1994: Isabelle Dubuc; Jean Costentin; J P Terranova; M C Barnouin; Philippe Soubrié; Gérard Le-Fur; William Rostène; Patrick Kitabgi
The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes.
British journal of pharmacology 1994;112(2):352-4.
1994: Régis Steinberg; P Brun; M Fournier; J Souilhac; Daniel Rodier; G Mons; J P Terranova; Gérard Le-Fur; Philippe Soubrié
SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission.
Neuroscience 1994;59(4):921-9.
1994: M Jung; R Calassi; J Maruani; M C Barnouin; J Souilhac; Martine Poncelet; Christiane Gueudet; Xavier Emonds-Alt; Philippe Soubrié; JC Brelière
Neuropharmacological characterization of SR 140333, a non peptide antagonist of NK1 receptors.
Neuropharmacology 1994;33(2):167-79.
1994: Régis Steinberg; I Bougault; J Souilhac; D Gully; Gérard Le-Fur; Philippe Soubrié
Blockade of neurotensin receptors by the antagonist SR 48692 partially prevents retrograde axonal transport of neurotensin in rat nigrostriatal system.
Neuroscience letters 1994;166(1):106-8.
1994: Martine Poncelet; Christiane Gueudet; D Gully; Philippe Soubrié; Gérard Le-Fur
Turning behavior induced by intrastriatal injection of neurotensin in mice: sensitivity to non-peptide neurotensin antagonists.
Naunyn-Schmiedeberg's archives of pharmacology 1994;349(1):57-60.
1993: J Fournier; Régis Steinberg; T Gauthier; Peter Keane; U Guzzi; F X Coudé; I Bougault; Jean-Pierre Maffrand; Philippe Soubrié; Gérard Le-Fur
Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates.
Neuroscience 1993;55(3):629-41.
1993: Xavier Emonds-Alt; Charles Advenier; Tiziano Croci; Luciano Manara; G Neliat; Martine Poncelet; V Proietto; Vincent Santucci; Philippe Soubrié; D Van Broeck
SR 48968, a neurokinin A (NK2) receptor antagonist.
Regulatory peptides 1993;46(1-2):31-6.
1993: Murielle Rinaldi-Carmona; Monsif Bouaboula; C Congy; Florence Oury-Donat; Jacques Simiand; David Shire; Pierre Casellas; Philippe Soubrié; JC Brelière; Gérard Le-Fur
Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist.
European journal of pharmacology 1993;246(1):73-80.
1993: Vincent Santucci; Christiane Gueudet; X Edmonds-Alt; JC Brelière; Philippe Soubrié; Gérard Le-Fur
The NK2 receptor antagonist SR48968 inhibits thalamic responses evoked by thermal but not mechanical nociception.
European journal of pharmacology 1993;237(1):143-6.
1993: Martine Poncelet; Vincent Santucci; R Paul; Christiane Gueudet; S Lavastre; J Guitard; Régis Steinberg; J P Terranova; JC Brelière; Philippe Soubrié
Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A.
Neuropharmacology 1993;32(6):605-15.
1993: C Labie; Peter Keane; Philippe Soubrié; Gérard Le-Fur
The sigma receptor ligand SR 31742A increases neurotensin in the nucleus accumbens but not in the caudate-putamen of the rat.
European journal of pharmacology 1993;231(3):465-7.
1993: Martine Poncelet; Christiane Gueudet; Xavier Emonds-Alt; JC Brelière; Gérard Le-Fur; Philippe Soubrié
Turning behavior induced in mice by a neurokinin A receptor agonist: stereoselective blockade by SR 48968, a non-peptide receptor antagonist.
Neuroscience letters 1993;149(1):40-2.
1993: M Didier; M Héaulme; N Gonalons; Philippe Soubrié; J Bockaert; J P Pin
35 mM K(+)-stimulated 45Ca2+ uptake in cerebellar granule cell cultures mainly results from NMDA receptor activation.
European journal of pharmacology 1993;244(1):57-65.
1993: A Bachy; Régis Steinberg; Vincent Santucci; M Fournier; M Landi; M Hamon; Luciano Manara; Peter Keane; Philippe Soubrié; Gérard Le-Fur
Biochemical and electrophysiological properties of SR 57746A, a new, potent 5-HT1A receptor agonist.
Fundamental & clinical pharmacology 1993;7(9):487-97.
1993: Jacques Simiand; Peter Keane; M C Barnouin; M Keane; Philippe Soubrié; Gérard Le-Fur
Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist.
Fundamental & clinical pharmacology 1993;7(8):413-27.
1992: Jacques Simiand; Peter Keane; J Guitard; X Langlois; N Gonalons; P Martin; Angelo Bianchetti; Gérard Le-Fur; Philippe Soubrié
Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors.
European journal of pharmacology 1992;219(2):193-201.
1990: M Didier; M Heaulme; Philippe Soubrié; J Bockaert; J P Pin
Rapid, sensitive, and simple method for quantification of both neurotoxic and neurotrophic effects of NMDA on cultured cerebellar granule cells.
Journal of neuroscience research 1990;27(1):25-35.
1990: S Ravard; P Carnoy; D Hervé; Jean-Pol Tassin; M H Thiébot; Philippe Soubrié
Involvement of prefrontal dopamine neurones in behavioural blockade induced by controllable vs uncontrollable negative events in rats.
Behavioural brain research 1990;37(1):9-18.
1990: P Martin; Philippe Soubrié; A J Puech
Reversal of helpless behavior by serotonin uptake blockers in rats.
Psychopharmacology 1990;101(3):403-7.
1989: Philippe Soubrié; P Martin; J Massol; G Gaudel
Attenuation of response to antidepressants in animals induced by reduction in food intake.
Psychiatry research 1989;27(2):149-59.
1989: P Martin; P Pichat; J Massol; Philippe Soubrié; K G Lloyd; A J Puech
Decreased GABA B receptors in helpless rats: reversal by tricyclic antidepressants.
Neuropsychobiology 1989;22(4):220-4.
1989: J Massol; P Martin; J P Belon; A J Puech; Philippe Soubrié
Helpless behavior (escape deficits) in streptozotocin-diabetic rats: resistance to antidepressant drugs.
Psychoneuroendocrinology 1989;14(1-2):145-53.
1988: J C Bizot; Marie-Hélène Thiébot; C Le Bihan; Philippe Soubrié; P Simon
Effects of imipramine-like drugs and serotonin uptake blockers on delay of reward in rats. Possible implication in the behavioral mechanism of action of antidepressants.
The Journal of pharmacology and experimental therapeutics 1988;246(3):1144-51.
1988: J Massol; P Martin; Philippe Soubrié; A J Puech
Triiodothyroacetic acid (TRIAC) potentiation of antidepressant-induced reversal of learned helplessness in rats.
European journal of pharmacology 1988;152(3):347-51.
1987: M Poncelet; P Martin; S Danti; P Simon; Philippe Soubrié
Noradrenergic rather than GABAergic processes as the common mediation of the antidepressant profile of GABA agonists and imipramine-like drugs in animals.
Pharmacology, biochemistry, and behavior 1987;28(3):321-6.
1987: P Martin; J Massol; J P Belon; G Gaudel; Philippe Soubrié
Thyroid function and reversal by antidepressant drugs of depressive-like behavior (escape deficits) in rats.
Neuropsychobiology 1987;18(1):21-6.
1986: Marie-Hélène Thiébot; C Le Bihan; Philippe Soubrié; P Simon
[Reduced waiting capacities as a possible mechanism of action of benzodiazepines. A hypothesis derived from their behavioral effects in animals].
L'Encéphale 1986;12(3):93-7.
1986: M Poncelet; G Gaudel; S Danti; Philippe Soubrié; P Simon
Acute versus repeated administration of desipramine in rats and mice: relationships between brain concentrations and reduction of immobility in the swimming test.
Psychopharmacology 1986;90(1):139-41.
1985: Marie-Hélène Thiébot; C Le Bihan; Philippe Soubrié; P Simon
Benzodiazepines reduce the tolerance to reward delay in rats.
Psychopharmacology 1985;86(1-2):147-52.